CD274 and neoplasm: In a related study, treatment with the combination therapy of 177Lu-DOTA-2P(FAPI)2 plus anti-PD-L1 monoclonal antibody resulted in a significant modulation of the tumor immune microenvironment, which was characterized by an increased infiltration of intratumoral T lymphocytes.